Janssen Therapeutics, a division of Janssen Products, announced that the U.S. Food and Drug Administration approved OLYSIO (simeprevir), an NS3/4A protease inhibitor.
The inhibitor has been approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen. OLYSIO works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics' Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation
The inhibitor has been approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen. OLYSIO works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.
More Articles on Supply Chain:
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics' Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation